|
|
The Body Covers:
The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy
Chicago, Illinois
September 14-17, 2003
|
Browse the complete index of our coverage.
Download the PDF version of our complete conference coverage (600K).
After the release of the guidelines is there a different understanding of when's the best time to start treatment? Judy Aberg, M.D., reports from ICAAC.
In a large comparison study of 1,119 antiretroviral-naive patients who started HIV therapy, treatment regimens containing efavirenz, nevirapine or Kaletra were found to be the most potent options. Gerald Pierone, Jr., M.D., reports."
"Both resistance testing and therapeutic drug monitoring are crucial tools to manage both treatment-naive and treatment-experienced patients. Mark Holodniy, M.D., explains why."
A Spanish study confirms ACTG 5095 and finds that the three-nucleoside regimen in Trizivir was not quite as potent as the efavirenz- or nevirapine-containing regimens for initial therapy. Andrew Pavia, M.D., reports.
|
|
|
|
|
|
Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
|
|
|
Advertisement
|